Investing.com - Citizens JMP has reiterated its Market Outperform rating and $81.00 price target on Mirum Pharmaceuticals (NASDAQ:MIRM), citing new preclinical data supporting PDE-4D inhibition in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback